SciClone has a substantial portfolio of products in China, including marketed products as well as those under development.
ZADAXIN® is approved in over 30 countries worldwide for several clinical indications, and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the approvals we have in these countries.
SciClone markets about 14, mostly partnered, products in China besides ZADAXIN, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace®, an ACE inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US), and Aggrastat®, a recently-launched intervention cardiology product.
Marketed Product Portfolio